Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciRS-7 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ciRS-7 siRNA is a small interfering RNA (siRNA) designed to target and knock down the circular RNA ciRS-7 (also known as CDR1-as). In various cancer models, including breast cancer and renal cell carcinoma, ciRS-7 acts as an oncogenic competing endogenous RNA (ceRNA) or 'sponge' that sequesters tumor-suppressive microRNAs such as miR-7-5p, miR-1299, and miR-139-3p. By silencing ciRS-7, ciRS-7 siRNA releases these microRNAs, leading to the downregulation of downstream oncogenic targets (such as CKS2, EGFR, and TAGLN), which subsequently suppresses cancer cell proliferation, migration, and invasion while promoting apoptosis. It is primarily utilized as a research-use-only laboratory tool to investigate circular RNA biology and the ciRS-7/miRNA regulatory axes.
- Other names
- CDR1as siRNACDR-1as siRNACDR 1as siRNAsi-CDR1assi-CDR-1assi-CDR 1assi-ciRS-7si-ciRS7si-ciRS 7
02
Targets
CDR1-AS (Cerebellar degeneration-related protein 1 antisense RNA)
Beyond the preview
Go deeper on ciRS-7 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciRS-7 siRNA.